Monday, August 31, 2009 8:37:25 AM
Press Release
Source: Sinovac Biotech Ltd.
On Monday August 31, 2009, 8:00 am EDT
Companies:Sinovac Biotech Ltd.
BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac's H1N1 vaccine has passed the experts evaluation organized by State Food and Drug Administration (SFDA). The vaccine is expected to obtain the production license within this week.
On August 30 and 31, 2009, State Food and Drug Administration (SFDA) organized and held an experts evaluation conference focused on A/H1N1 vaccines to evaluate Sinovac's H1N1 vaccine, which has recently completed a clinical trial. Top-line results from the trial demonstrated Sinovac's H1N1 vaccine to have a good safety profile and immunogenicity factors that reach the EU criterion after a single shot. No severe adverse events were reported after inoculation. Based on the results of the evaluation, the experts unanimously agreed that Sinovac's H1N1 vaccine is applicable to all people from 3 to 60 years old and the vaccination schedule is single shot. The result of the experts evaluation conference will be submitted to SFDA on September 1st, which will be the primary opinion for SFDA to issue the production license.
Sinovac submitted the H1N1 split influenza vaccine without adjuvant for registration approval, which is applicable to all people from 3 to 60 years old. The dosage is 15ug/0.5ml/dose. Only one shot is needed for inoculation.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac commented, "We are very excited to see that our H1N1 vaccine has passed the experts evaluation conference organized by SFDA. The evaluation result will be the important opinion for SFDA to issue the production license. We expect to obtain the production license within one week. With this approval, we can continue to fulfill our mission to provide top-quality vaccines to prevent and control the spreading of H1N1 virus not only in China, but worldwide."
Recent SVA News
- SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F • Business Wire • 04/29/2024 09:53:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 02/21/2024 11:09:13 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 11:02:10 AM
- Sinovac Amends Shareholder Rights Plan • Business Wire • 02/21/2024 07:56:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 02/02/2024 04:19:55 PM
- シノバック取締役会、一方的な部分公開買い付けを全会一致で退ける • Business Wire • 01/19/2024 11:58:00 AM
- Sinovac董事會一致反對Alternative Liquidity主動提出的部分公開收購方案 • Business Wire • 01/18/2024 07:54:00 PM
- Le conseil d'administration de Sinovac rejette à l'unanimité une offre partielle non sollicitée • Business Wire • 01/18/2024 07:47:00 PM
- Das Board of Directors von Sinovac lehnt einstimmig ein unaufgefordert abgegebenes Teilkaufangebot ab • Business Wire • 01/18/2024 06:33:00 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 01/18/2024 12:13:31 PM
- Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer • Business Wire • 01/18/2024 12:00:00 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 01/08/2024 09:46:34 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/04/2023 11:01:59 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 10/03/2023 01:39:57 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 09/15/2023 12:59:40 PM
- シノバック、新型コロナウイルスに対するSA55抗体注射剤の臨床試験について進展を報告 • Business Wire • 09/12/2023 10:10:00 AM
- SINOVAC rend compte des progrès réalisés dans le cadre de son essai clinique concernant l’injection anti-COVID-19 à base d’anticorps SA55 • Business Wire • 09/11/2023 02:36:00 PM
- SINOVAC informiert über die Fortschritte bei der klinischen Studie für den Anti-COVID-19-Antikörper SA55 Injection • Business Wire • 09/11/2023 02:36:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 10:16:45 AM
- SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection • Business Wire • 09/11/2023 09:55:00 AM
- シノバック取締役会、同意なき株式の部分公開買付を全会一致で拒否 • Business Wire • 09/06/2023 11:35:00 AM
- Sinovac-Vorstand lehnt ein unangefordertes Teilübernahmeangebot einstimmig ab • Business Wire • 09/05/2023 04:16:00 PM
- Le conseil d’administration de Sinovac rejette à l’unanimité une offre publique d’achat partielle non sollicitée • Business Wire • 09/05/2023 03:36:00 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 09/05/2023 11:04:01 AM
- Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer • Business Wire • 09/05/2023 08:12:00 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM